Climb Bio (CLYM) Research & Development (2020 - 2026)
Climb Bio (CLYM) posted Research & Development of $9.4 million for Q1 2026, down 31.77% on a QoQ basis from $13.7 million in Q4 2025, and down 45.91% year-over-year from $17.3 million in Q1 2025.
Climb Bio (CLYM) Research & Development (2020 - 2026) Analysis & Trends
Climb Bio's Research & Development history runs 7 years deep, the most recent figure standing at $9.4 million for Q1 2026.
- Quarterly Research & Development fell 45.91% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.8 million (up 26.78% YoY) and the FY2025 annual result came in at $46.7 million, up 225.84% from the prior year.
- Research & Development was $9.4 million for Q1 2026 at Climb Bio, down from $13.7 million in the prior quarter.
- Across five years, Research & Development topped out at $17.3 million in Q1 2025 and bottomed at $1.0 million in Q2 2024.
- A 5-year average of $6.6 million and a median of $6.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 80.93% — and 2025, when it soared 1488.18%.
- Climb Bio's Research & Development stood at $4.9 million in 2022, then plunged by 36.53% to $3.1 million in 2023, then jumped by 90.57% to $6.0 million in 2024, then soared by 130.54% to $13.7 million in 2025, then sank by 31.77% to $9.4 million in 2026.
- Business Quant data shows CLYM's Research & Development at $9.4 million in Q1 2026, $13.7 million in Q4 2025, and $9.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | 9.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.37 Mn |
| Dec 31, 2025 | 13.74 Mn |
| Sep 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 17.33 Mn |
| Dec 31, 2024 | 5.96 Mn |
| Sep 30, 2024 | 6.24 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 3.69 Mn |
| Mar 31, 2023 | 5.72 Mn |
| Dec 31, 2022 | 4.93 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 8.77 Mn |
| Mar 31, 2022 | 8.26 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 5.99 Mn |
| Jun 30, 2021 | 5.48 Mn |